Privately held Ensemble Therapeutics Corp. revealed its latest platform partnership with a pharma Nov. 1, striking a multi-compound deal with Boehringer Ingelheim GMBH to discover novel drugs for difficult-to-reach targets involving protein-protein interactions.
Most terms of the deal weren’t released, including the size of the up-front payment, number of drugs involved, and amount...